Table 3 Data from the exercise test of the study participants who completed baseline and follow up testing (n = 55) presented by before treatment and after six month follow up, stratified by treatment group. Data are given as mean with confidence intervals (CI) and standard deviation (SD) in parentheses unless otherwise stated*
| Â | Â | Before treatment mean (SD) | 95% CI | Six month follow up mean (SD) | 95% CI | P-valueb |
|---|---|---|---|---|---|---|
Chemotherapy (N = 20) | VO2max (ml kg−1. min− 1) | 31 (7.1) | 27.6–34.3 | 28.7 (6.2) | 25.8–31.6 | .191 |
VE peak (L min− 1) | 84 (15.4) | 76.8–91.2 | 82.4 (19.4) | 73.3–91.5 | .296 | |
RER peak | 1.25 (0.1) | 1.22–1.29 | 1.22 (0.1) | 1.17–1.27 | .147 | |
RPE peak | 17.2 (1.2) | 16.6–17.8 | 17.8 (1.2) | 17.2–18.3 | .058 | |
HR peak (beats. min−1) | 173 (13) | 166.5–178.6 | 170 (11.1) | 164.3–174.6 | .054 | |
Radiotherapy (N = 18) | VO2max (ml kg−1. min− 1) | 29.4 (6.7) | 26.1–32.7 | 29.4 (7.9) | 25.5–33.3 | .794 |
VE peak (L min− 1) | 77.8 (18.7) | 68.5–87.1 | 73.5 (28.2) | 59.4–87.5 | .845 | |
RER peak | 1.20 (0.1) | 1.15–1.25 | 1.17 (0.1) | 1.12–1.23 | .140 | |
RPE peak | 16.6 (1.3) | 15.9–17.2 | 17.2 (1.5) | 16.4–17.9 | .031* | |
HR peak (beats. min−1) | 169 (20.4) | 158.6–178.9 | 165 (16.4) | 156.7–173 | .138 | |
Endocrine therapy (N = 17) | VO2max (ml kg− 1. min− 1) | 32 (6.8) | 28.5–35.5 | 33.1 (9.2) | 28.4–37.8 | .162 |
VE peak (L min− 1) | 86.6 (18.6) | 77.1–96.2 | 83.7 (17.2) | 74.8–92.5 | .113 | |
RER peak | 1.23 (0.1) | 1.16–1.30 | 1.19 (0.1) | 1.13–1.24 | .162 | |
RPE peak | 17.4 (1.2) | 16.8–18 | 17.2 (1.7) | 16.3–18.1 | .558 | |
HR peak (beats. min−1) | 166 (17.8) | 156.9–175.2 | 166 (19.7) | 156.2–176.4 | .816 |